286 related articles for article (PubMed ID: 37196221)
1. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy.
Zong Y; Lin Y; Wei T; Cheng Q
Adv Mater; 2023 Dec; 35(51):e2303261. PubMed ID: 37196221
[TBL] [Abstract][Full Text] [Related]
2. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
3. Current status and patent prospective of lipid nanoparticle for mRNA delivery.
Zhang HL
Expert Opin Ther Pat; 2023 Feb; 33(2):125-131. PubMed ID: 36958374
[TBL] [Abstract][Full Text] [Related]
4. Current Status and Future Perspectives on MRNA Drug Manufacturing.
Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK
Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565
[TBL] [Abstract][Full Text] [Related]
5. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
Wang C; Zhang Y; Dong Y
Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
[TBL] [Abstract][Full Text] [Related]
6. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
7. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs.
Suzuki Y; Ishihara H
Drug Metab Pharmacokinet; 2021 Dec; 41():100424. PubMed ID: 34757287
[TBL] [Abstract][Full Text] [Related]
8. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
9. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.
Maeki M; Uno S; Niwa A; Okada Y; Tokeshi M
J Control Release; 2022 Apr; 344():80-96. PubMed ID: 35183654
[TBL] [Abstract][Full Text] [Related]
10. mRNA delivery technologies: Toward clinical translation.
Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
[TBL] [Abstract][Full Text] [Related]
11. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
12. Insights into the Structure of Comirnaty Covid-19 Vaccine: A Theory on Soft, Partially Bilayer-Covered Nanoparticles with Hydrogen Bond-Stabilized mRNA-Lipid Complexes.
Szebeni J; Kiss B; Bozó T; Turjeman K; Levi-Kalisman Y; Barenholz Y; Kellermayer M
ACS Nano; 2023 Jul; 17(14):13147-13157. PubMed ID: 37417667
[TBL] [Abstract][Full Text] [Related]
13. Development and applications of mRNA treatment based on lipid nanoparticles.
Wang Z; Ma W; Fu X; Qi Y; Zhao Y; Zhang S
Biotechnol Adv; 2023; 65():108130. PubMed ID: 36933868
[TBL] [Abstract][Full Text] [Related]
14. Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics.
Semple SC; Leone R; Barbosa CJ; Tam YK; Lin PJC
Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214130
[TBL] [Abstract][Full Text] [Related]
15. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
Shepherd SJ; Han X; Mukalel AJ; El-Mayta R; Thatte AS; Wu J; Padilla MS; Alameh MG; Srikumar N; Lee D; Weissman D; Issadore D; Mitchell MJ
Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303567120. PubMed ID: 37556502
[TBL] [Abstract][Full Text] [Related]
16. Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8
Chen J; Ye Z; Huang C; Qiu M; Song D; Li Y; Xu Q
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2207841119. PubMed ID: 35969778
[TBL] [Abstract][Full Text] [Related]
17. Development of a high-throughput platform for screening lipid nanoparticles for mRNA delivery.
Cui L; Pereira S; Sonzini S; van Pelt S; Romanelli SM; Liang L; Ulkoski D; Krishnamurthy VR; Brannigan E; Brankin C; Desai AS
Nanoscale; 2022 Jan; 14(4):1480-1491. PubMed ID: 35024714
[TBL] [Abstract][Full Text] [Related]
18. Spray dried lipid nanoparticle formulations enable intratracheal delivery of mRNA.
Friis KP; Gracin S; Oag S; Leijon A; Sand E; Lindberg B; Lázaro-Ibáñez E; Lindqvist J; Whitehead KA; Bak A
J Control Release; 2023 Nov; 363():389-401. PubMed ID: 37741463
[TBL] [Abstract][Full Text] [Related]
19. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
Schoenmaker L; Witzigmann D; Kulkarni JA; Verbeke R; Kersten G; Jiskoot W; Crommelin DJA
Int J Pharm; 2021 May; 601():120586. PubMed ID: 33839230
[TBL] [Abstract][Full Text] [Related]
20. Design Strategies for and Stability of mRNA-Lipid Nanoparticle COVID-19 Vaccines.
Liu T; Tian Y; Zheng A; Cui C
Polymers (Basel); 2022 Oct; 14(19):. PubMed ID: 36236141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
